BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 9391160)

  • 1. Molecular determinants of tissue selectivity in estrogen receptor modulators.
    Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
    Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
    J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
    Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
    J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
    Sato M; Rippy MK; Bryant HU
    FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site.
    Weatherman RV; Carroll DC; Scanlan TS
    Bioorg Med Chem Lett; 2001 Dec; 11(24):3129-31. PubMed ID: 11720858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
    Palkowitz AD; Glasebrook AL; Thrasher KJ; Hauser KL; Short LL; Phillips DL; Muehl BS; Sato M; Shetler PK; Cullinan GJ; Pell TR; Bryant HU
    J Med Chem; 1997 May; 40(10):1407-16. PubMed ID: 9154963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
    Suh N; Glasebrook AL; Palkowitz AD; Bryant HU; Burris LL; Starling JJ; Pearce HL; Williams C; Peer C; Wang Y; Sporn MB
    Cancer Res; 2001 Dec; 61(23):8412-5. PubMed ID: 11731420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
    Sömjen D; Waisman A; Kaye AM
    J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity.
    Dodge JA; Lugar CW; Cho S; Short LL; Sato M; Yang NN; Spangle LA; Martin MJ; Phillips DL; Glasebrook AL; Osborne JJ; Frolik CA; Bryant HU
    J Steroid Biochem Mol Biol; 1997 Apr; 61(1-2):97-106. PubMed ID: 9328215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.
    Paech K; Webb P; Kuiper GG; Nilsson S; Gustafsson J; Kushner PJ; Scanlan TS
    Science; 1997 Sep; 277(5331):1508-10. PubMed ID: 9278514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
    Bryant HU; Dere WH
    Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity.
    Jones CD; Jevnikar MG; Pike AJ; Peters MK; Black LJ; Thompson AR; Falcone JF; Clemens JA
    J Med Chem; 1984 Aug; 27(8):1057-66. PubMed ID: 6431104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
    Willson TM; Norris JD; Wagner BL; Asplin I; Baer P; Brown HR; Jones SA; Henke B; Sauls H; Wolfe S; Morris DC; McDonnell DP
    Endocrinology; 1997 Sep; 138(9):3901-11. PubMed ID: 9275080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An estrogen receptor basis for raloxifene action in bone.
    Bryant HU; Glasebrook AL; Yang NN; Sato M
    J Steroid Biochem Mol Biol; 1999; 69(1-6):37-44. PubMed ID: 10418979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the "estrogenicity" of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes.
    Barkhem T; Andersson-Ross C; Höglund M; Nilsson S
    J Steroid Biochem Mol Biol; 1997 May; 62(1):53-64. PubMed ID: 9366498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.
    Greschik H; Flaig R; Renaud JP; Moras D
    J Biol Chem; 2004 Aug; 279(32):33639-46. PubMed ID: 15161930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of raloxifene hydrochloride in women.
    Khovidhunkit W; Shoback DM
    Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha.
    Dayan G; Lupien M; Auger A; Anghel SI; Rocha W; Croisetière S; Katzenellenbogen JA; Mader S
    Mol Pharmacol; 2006 Aug; 70(2):579-88. PubMed ID: 16679488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multiplexed screening method for agonists and antagonists of the estrogen receptor protein.
    Li Z; Yan M; Li Z; Vuki M; Wu D; Liu F; Zhong W; Zhang L; Xu D
    Anal Bioanal Chem; 2012 May; 403(5):1373-84. PubMed ID: 22453607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.